Skip to main content
Year archive

ACTINOGEN MEDICAL LIMITED — 2018 filings

All 87 regulatory filings released by ACTINOGEN MEDICAL LIMITED (ACW) in 2018, sourced directly from the official regulator.

87 Filings
2018 Period
2018 filings (87)
Filing Released Lang
Appendix 3B 12 pages 161.7KB
Share Issue/Capital Change
2018-12-12 English
Appendix 3y-Dr Geoff Brooke 2 pages 28.3KB
Director's Dealing
2018-12-12 English
Appendix 3Y-Dr Bill Ketelbey 2 pages 28.0KB
Director's Dealing
2018-12-12 English
Appendix 3Y-Dr George Morstyn 2 pages 28.2KB
Director's Dealing
2018-12-12 English
Appendix 3B-Exercise of Options 12 pages 165.4KB
Share Issue/Capital Change
2018-11-29 English
Cleansing Notice 1 page 105.5KB
Share Issue/Capital Change
2018-11-29 English
Chairman's AGM Address 3 pages 92.9KB
AGM Information
2018-11-27 English
Managing Director's AGM Presentation 23 pages 1.2MB
AGM Information
2018-11-27 English
Results of Annual General Meeting 4 pages 189.8KB
Declaration of Voting Results & Voting Rights Announcements
2018-11-27 English
Retirement of Dr Jason Loveridge as a Non-Executive Director 2 pages 138.7KB
Board/Management Information
2018-11-27 English
Appendix 3Z-Dr Jason Loveridge 2 pages 28.7KB
Director's Dealing
2018-11-27 English
Actinogen updated investor presentation 39 pages 2.6MB
Investor Presentation
2018-11-25 English
Final patient enrolled in landmark Alzheimer's trial-XanADu 2 pages 138.9KB
Regulatory Filings
2018-11-25 English
Appendix 3B-Exercise of Options 12 pages 165.8KB
Capital/Financing Update
2018-11-13 English
Cleansing Notice 1 page 105.5KB
Capital/Financing Update
2018-11-13 English
Supportive research highlights cortisol hypothesis 2 pages 187.6KB
Regulatory Filings
2018-11-07 English
Vesting Conditions Met 2 pages 139.2KB
Regulatory Filings
2018-10-30 English
September 2018 Quarterly Update 9 pages 251.5KB
Interim / Quarterly Report
2018-10-30 English
Actinogen to be showcased at AusBiotech Invest 2018 13 pages 604.6KB
Investor Presentation
2018-10-29 English
Enrolment target achieved for major Alzheimer's trial-XanADu 2 pages 139.3KB
Regulatory Filings
2018-10-28 English
XanADu trial to be presented at global Alzheimer conference 2 pages 144.8KB
Regulatory Filings
2018-10-23 English
Notice of Annual General Meeting/Proxy Form 27 pages 477.0KB
AGM Information
2018-10-22 English
Annual Report to Shareholders 90 pages 1.7MB
Annual Report
2018-10-22 English
Recruitment to close for important Alzheimer's trial-XanADu 2 pages 141.1KB
Regulatory Filings
2018-10-21 English
Actinogen to be showcased at key conferences 21 pages 1.1MB
Investor Presentation
2018-10-16 English
Becoming a substantial holder from AEF 3 pages 439.3KB
Major Shareholding Notification
2018-10-15 English
R&D Tax Rebate Received Totalling $3.15 Million 2 pages 144.9KB
Regulatory Filings
2018-10-09 English
Notification of 2018 Annual General Meeting Date 2 pages 133.0KB
AGM Information
2018-09-27 English
Appendix 3B-Exercise of Options 12 pages 166.5KB
Share Issue/Capital Change
2018-09-17 English
Cleansing Notice 1 page 105.4KB
Share Issue/Capital Change
2018-09-17 English
Actinogen to Present to Investors in Singapore & Sydney 29 pages 1.4MB
Regulatory Filings
2018-09-10 English
Appendix 4E & Financial Statements 92 pages 1.6MB
Annual Report
2018-08-28 English
Appendix 4G 8 pages 149.3KB
Governance Information
2018-08-28 English
DSMB reaffirms that XanADu continue without change 2 pages 139.8KB
Capital/Financing Update
2018-08-21 English
XanADu Patient Enrolment Advancing Towards Completion 2 pages 166.7KB
Regulatory Filings
2018-08-14 English
Updated Xanamem Clinical Development Program 2 pages 142.6KB
Capital/Financing Update
2018-07-29 English
June 2018 Quarterly Report 8 pages 226.6KB
Interim / Quarterly Report
2018-07-24 English
Ceasing to be a substantial holder 1 page 68.0KB
Major Shareholding Notification
2018-07-23 English
Appendix 3B 12 pages 167.5KB
Share Issue/Capital Change
2018-07-23 English
Cleansing Notice 1 page 105.5KB
Share Issue/Capital Change
2018-07-23 English
Placement under Share Purchase Plan Shortfall 2 pages 144.9KB
Capital/Financing Update
2018-07-16 English
Appendix 3Y-Dr Geoff Brooke 2 pages 27.3KB
Director's Dealing
2018-07-15 English
Appendix 3Y-Dr Bill Ketelbey 2 pages 27.3KB
Director's Dealing
2018-07-15 English
Appendix 3B-Share Purchase Plan 12 pages 166.6KB
Capital/Financing Update
2018-07-12 English
Appendix 3B 12 pages 166.7KB
Capital/Financing Update
2018-07-11 English
Cleansing Notice 1 page 104.3KB
Capital/Financing Update
2018-07-11 English
Share Purchase Plan Completed 2 pages 158.5KB
Capital/Financing Update
2018-07-11 English
New Study Sites Added to Accelarate Patient Recruitment 2 pages 138.4KB
Regulatory Filings
2018-07-05 English
Results of Meeting 3 pages 186.0KB
Declaration of Voting Results & Voting Rights Announcements
2018-07-04 English
Appendix 3B - Exercise of Options 12 pages 166.4KB
Share Issue/Capital Change
2018-07-04 English
Cleansing Notice 1 page 104.3KB
Capital/Financing Update
2018-07-04 English
Change of Address 1 page 129.2KB
Regulatory Filings
2018-06-18 English
Share Purchase Plan 7 pages 264.3KB
Share Issue/Capital Change
2018-06-05 English
Appendix 3Y-Dr George Morstyn 2 pages 26.9KB
Director's Dealing
2018-06-04 English
Notice of General Meeting/Proxy Form 10 pages 313.6KB
Proxy Solicitation & Information Statement
2018-06-04 English
Change in substantial holding 2 pages 120.3KB
Regulatory Filings
2018-05-30 English
Actinogen Medical to present at BIO International 2018 26 pages 2.2MB
Investor Presentation
2018-05-30 English
Becoming a substantial holder 35 pages 1.0MB
Regulatory Filings
2018-05-30 English
Ceasing to be a substantial holder 2 pages 143.4KB
Regulatory Filings
2018-05-29 English
Actinogen Medical Investor Conference Call 26 pages 1.1MB
Call Transcript
2018-05-27 English
Appendix 3B 12 pages 168.1KB
Share Issue/Capital Change
2018-05-27 English
Cleansing Notice 1 page 103.7KB
Share Issue/Capital Change
2018-05-27 English
Information Required Under ASX Listing Rule 3.10.5A 1
Capital/Financing Update
2018-05-27 English
XanADu Interim Analysis-Continuation Without Change 2 pages 200.8KB
Interim / Quarterly Report
2018-05-22 English
$15m Placement Completed-Including US Cornerstone Investor 3 pages 217.8KB
Capital/Financing Update
2018-05-22 English
Trading Halt 3 pages 213.5KB
Regulatory Filings
2018-05-20 English
Appendix 3B-Exercise of Options 12 pages 159.4KB
Capital/Financing Update
2018-05-13 English
Cleansing Notice 1 page 103.4KB
Share Issue/Capital Change
2018-05-13 English
XanADu Interim Analysis on track for May/June 1 pag
Regulatory Filings
2018-05-09 English
March 2018 Quarterly Report 8 pages 263.7KB
Interim / Quarterly Report
2018-04-25 English
Appendix 3B-Exercise of Options 12 pages 160.1KB
Capital/Financing Update
2018-04-17 English
Cleansing Notice 1 page 103.4KB
Share Issue/Capital Change
2018-04-17 English
New Analyst Report on Actinogen Medical 2 pages 131.1KB
Report Publication Announcement
2018-04-10 English
Appendix 3B 12 pages 163.8KB
Share Issue/Capital Change
2018-04-02 English
Mid-Way Point Reached in Landmark Alzheimer's Trial - XanADu 2 pages 165.9KB
Regulatory Filings
2018-03-20 English
Investor Presentation 25 pages 1.9MB
Investor Presentation
2018-03-18 English
Invitation to Investor Briefing 2 pages 191.6KB
Investor Presentation
2018-03-06 English
Appendix 4D & Half-Year Financial Statements 26 pages 929.3KB
Interim / Quarterly Report
2018-02-14 English
Strong Recruitment Progress in Alzheimer's Trial 2 pages 142.5KB
Regulatory Filings
2018-02-11 English
New Data Supports Cortisol Hypothesis 2 pages 216.8KB
Regulatory Filings
2018-02-05 English
December 2017 Quarterly Report 8 pages 248.3KB
Interim / Quarterly Report
2018-01-30 English
Change in substantial holding 2 pages 1.2MB
Regulatory Filings
2018-01-28 English
Appendix 3B 12 pages 160.6KB
Capital/Financing Update
2018-01-21 English
Cleansing Notice 1 page 103.9KB
Capital/Financing Update
2018-01-21 English
Appendix 3Y-Dr Geoff Brooke 2 pages 27.3KB
Director's Dealing
2018-01-21 English
Results of Meeting 3 pages 186.3KB
Declaration of Voting Results & Voting Rights Announcements
2018-01-17 English
Lapse of Unlisted Options 1 page 99.0KB
Capital/Financing Update
2018-01-01 English